©The Author(s) 2026.
World J Immunol. Jan 8, 2026; 16(1): 111511
Published online Jan 8, 2026. doi: 10.5411/wji.v16.i1.111511
Published online Jan 8, 2026. doi: 10.5411/wji.v16.i1.111511
Figure 15 Diagrammatic representation of zingerone-mediated protection against diabetes mellitus induced harms to kidneys, heart, liver, and eyes.
TG: Triglycerides; LDL: Low density lipoprotein; VLDL: Very low density lipoprotein; HDL: High density lipoproteins; NF-κB: Nuclear factor kappa B; IL: Interleukin; TNF-α: Tumor necrosis factor alpha; iNOS: Inducible nitric oxide synthase.
- Citation: Singh B, Singh H, Kaur S, Singh B. Preclinical pharmacology studies of zingerone with special reference to potential therapeutic applications. World J Immunol 2026; 16(1): 111511
- URL: https://www.wjgnet.com/2219-2824/full/v16/i1/111511.htm
- DOI: https://dx.doi.org/10.5411/wji.v16.i1.111511